Elizabeth Bortolon

840 total citations
9 papers, 443 citations indexed

About

Elizabeth Bortolon is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Elizabeth Bortolon has authored 9 papers receiving a total of 443 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Elizabeth Bortolon's work include Protein Degradation and Inhibitors (7 papers), Peptidase Inhibition and Analysis (4 papers) and Advanced Breast Cancer Therapies (2 papers). Elizabeth Bortolon is often cited by papers focused on Protein Degradation and Inhibitors (7 papers), Peptidase Inhibition and Analysis (4 papers) and Advanced Breast Cancer Therapies (2 papers). Elizabeth Bortolon collaborates with scholars based in United States and France. Elizabeth Bortolon's co-authors include Yong S. Chang, Scott M. Wilhelm, Arris J. Henderson, Joan Levy, Mark Lynch, Marina Ichetovkin, Pamela A. Trail, Dean Wilkie, I Taylor and Christopher A. Carter and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Molecular Cancer Research.

In The Last Decade

Elizabeth Bortolon

8 papers receiving 433 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elizabeth Bortolon United States	5	205	171	111	104	101	9	443
Marina Ichetovkin United States	5	319 1.6×	171 1.0×	202 1.8×	124 1.2×	109 1.1×	6	632
Marianna Silletta Italy	14	157 0.8×	171 1.0×	224 2.0×	87 0.8×	214 2.1×	42	613
P. Kupsch Germany	7	196 1.0×	87 0.5×	206 1.9×	59 0.6×	109 1.1×	11	389
M. Grubert Germany	9	153 0.7×	82 0.5×	163 1.5×	44 0.4×	85 0.8×	13	362
Sean Clark-Garvey United States	4	218 1.1×	289 1.7×	176 1.6×	96 0.9×	64 0.6×	12	569
Van Chanh Ngo Singapore	6	319 1.6×	250 1.5×	111 1.0×	103 1.0×	87 0.9×	6	570
Seok-Hyun Kim South Korea	8	250 1.2×	64 0.4×	191 1.7×	87 0.8×	55 0.5×	16	447
Nikol Snoeren Netherlands	12	203 1.0×	149 0.9×	232 2.1×	169 1.6×	88 0.9×	16	522
Qinguo Mo China	14	165 0.8×	160 0.9×	144 1.3×	213 2.0×	88 0.9×	27	606
Kateřina Kopečková Czechia	13	152 0.7×	45 0.3×	220 2.0×	100 1.0×	137 1.4×	61	477

Countries citing papers authored by Elizabeth Bortolon

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Bortolon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Bortolon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Bortolon more than expected).

Fields of papers citing papers by Elizabeth Bortolon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Bortolon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Bortolon. The network helps show where Elizabeth Bortolon may publish in the future.

Co-authorship network of co-authors of Elizabeth Bortolon

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Bortolon. A scholar is included among the top collaborators of Elizabeth Bortolon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Bortolon. Elizabeth Bortolon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

DeCarr, Lynn B., Samantha L. Eaton, Deborah Witt Sherman, et al.. (2025). ABCL-796: ARV-393, a PROTAC BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors (SMIs) Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma (DLBCL) Models. Clinical Lymphoma Myeloma & Leukemia. 25. S760–S760.

DeCarr, Lynn B., Elizabeth Bortolon, Mark Bookbinder, et al.. (2025). Abstract 1655: ARV-393, a PROTAC B-cell lymphoma 6 (BCL6) degrader, combined with biologics or small molecule inhibitors (SMIs) induces tumor regressions in diffuse large B-cell lymphoma (DLBCL) models. Cancer Research. 85(8_Supplement_1). 1655–1655. 1 indexed citations

Zhang, Donglu, Bin Ma, Peter S. Dragovich, et al.. (2024). Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs. SHILAP Revista de lepidopterología. 4(1). 87–87. 8 indexed citations

Levy, Elizabeth S., An D. Nguyen, Donglu Zhang, et al.. (2023). Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs. Pharmaceutics. 15(8). 2098–2098. 12 indexed citations

Wu, Wendy, Monica Andreoli, Elizabeth Bortolon, et al.. (2023). Abstract 432: Mechanisms of acquired resistance to ARV-471, a novel PROTAC® estrogen receptor degrader. Cancer Research. 83(7_Supplement). 432–432. 3 indexed citations

Bortolon, Elizabeth, et al.. (2023). Abstract 3075: Enhanced efficacy of ARV-471, a novel PROTAC® estrogen receptor degrader, in combination with targeted agents in estrogen receptor-positive (ER+) breast cancer models. Cancer Research. 83(7_Supplement). 3075–3075. 4 indexed citations

Smith, Kathryn E., Peter T. Nower, Jennifer Pizzano, et al.. (2023). Abstract PR09: KRAS-targeted PROTAC degraders are broadly efficacious against KRAS-dependent tumor models. Molecular Cancer Research. 21(5_Supplement). PR09–PR09. 2 indexed citations

Levy, Joan, Déborah Braun, Mary DeRome, et al.. (2006). Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Cancer Research. 66. 213–214. 25 indexed citations

Chang, Yong S., Jalila Adnane, Pamela A. Trail, et al.. (2006). Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemotherapy and Pharmacology. 59(5). 561–574. 388 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact